3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
30
Neoplasm Metastasis
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Radiation Injuries
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligometastatic Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Prednisone
2
Abiraterone Acetate
2
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
apalutamide
1
Standard of Care
1
Radiosurgery
1
Hydrocortisone
1
Docetaxel
1
Dexamethasone
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Metastatic
×
Androgen Antagonists
×
90 days
×
Clear all
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled